Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-06-20 07:30 am Purchase | 13D | Akari Therapeutics Plc AKTX | RPC Pharma Ltd | 4,507,314,800 19.200% | 1,022,356,900 (+29.34%) | View |
| 2024-01-04 12:34 pm Purchase | 13D | Akari Therapeutics Plc AKTX | RPC Pharma Ltd | 3,484,957,900 26.400% | 3,484,957,900 (New Position) | View |
| 2023-10-20 5:00 pm Purchase | 13D | Akari Therapeutics Plc AKTX | RPC Pharma Ltd | 2,537,089,900 21.800% | 242,185,000 (+10.55%) | View |
| 2023-04-14 4:06 pm Purchase | 13D | Akari Therapeutics Plc AKTX | RPC Pharma Ltd | 2,294,904,900 22.700% | 1,360,758,700 (+145.67%) | View |
| 2022-01-14 4:18 pm Purchase | 13D | Akari Therapeutics Plc AKTX | RPC Pharma Ltd | 934,146,200 18.000% | 40,459,500 (+4.53%) | View |
| 2021-10-18 5:06 pm Purchase | 13D | Akari Therapeutics Plc AKTX | RPC Pharma Ltd | 893,686,700 18.800% | 61,209,600 (+7.35%) | View |
| 2020-03-30 4:52 pm Purchase | 13D | Akari Therapeutics Plc AKTX | RPC Pharma Ltd | 832,477,100 28.800% | 50,131,500 (+6.41%) | View |